Vericel Corp
VCEL
Company Profile
Business description
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Contact
64 Sidney Street
CambridgeMA02139
USAT: +1 617 588-5555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
357
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.70 | 43.70 | 0.52% |
| CAC 40 | 7,873.83 | 23.73 | 0.30% |
| DAX 40 | 23,638.56 | 72.02 | 0.31% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,602.92 | 2.06 | -0.02% |
| HKSE | 23,108.27 | 441.19 | -1.87% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 38,183.26 | 539.00 | 1.43% |
| NZX 50 Index | 12,781.18 | 5.56 | -0.04% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,269.00 | 35.50 | 0.43% |
| SSE Composite Index | 3,374.87 | 5.63 | 0.17% |